OTCMKTS:DCHPF

Dechra Pharmaceuticals (DCHPF) Stock Price, News & Analysis

$46.90
0.00 (0.00%)
(As of 01/18/2024)
Today's Range
$46.90
$46.90
50-Day Range
$46.90
$46.90
52-Week Range
$30.00
$47.40
Volume
N/A
Average Volume
1,687 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DCHPF stock logo

About Dechra Pharmaceuticals Stock (OTCMKTS:DCHPF)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

DCHPF Stock Price History

DCHPF Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
See More Headlines
Receive DCHPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTCMKTS:DCHPF
CIK
N/A
Fax
N/A
Employees
2,457
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Ian D. Page (Age 63)
    CEO, MD & Executive Director
    Comp: $1.08M
  • Mr. Paul Nicholas Sandland MAAT (Age 45)
    FCCA, CFO & Executive Director
    Comp: $711.5k

DCHPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DCHPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCHPF, but not buy additional shares or sell existing shares.
View DCHPF analyst ratings
or view top-rated stocks.

How have DCHPF shares performed in 2024?

Dechra Pharmaceuticals' stock was trading at $46.90 at the beginning of the year. Since then, DCHPF stock has increased by 0.0% and is now trading at $46.90.
View the best growth stocks for 2024 here
.

How do I buy shares of Dechra Pharmaceuticals?

Shares of DCHPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:DCHPF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners